Abstract:MTOR (mechanistic target of rapamycin kinase) complex 1 (MTORC1) orchestrates diverse environmental signals to facilitate cell growth and is frequently activated in cancer. Translocation of MTORC1 from the cytosol to the lysosomal surface by the RRAG GTPases is the key step in MTORC1 activation. Here, we demonstrated that transcription factors MEF2A and MEF2D synergistically regulated MTORC1 activation via modulating its cyto-lysosome shutting. Mechanically, MEF2A and MEF2D controlled the transcription of FNIP1 and FNIP2, the components of the FLCN-FNIP1 or FNIP2 complex that acts as a RRAGC-RRAGD GTPase-activating element to promote the recruitment of MTORC1 to lysosome and its activation. Furthermore, we determined that the pro-oncogenic protein kinase SRC/c-Src directly phosphorylated MEF2D at three conserved tyrosine residues. The tyrosine phosphorylation enhanced MEF2D transcriptional activity and was indispensable for MTORC1 activation. Finally, both the protein and tyrosine phosphorylation levels of MEF2D are elevated in human pancreatic cancers, positively correlating with MTORC1 activity. Depletion of both MEF2A and MEF2D or expressing the unphosphorylatable MEF2D mutant suppressed tumor cell growth. Thus, our study revealed a transcriptional regulatory mechanism of MTORC1 that promoted cell anabolism and proliferation and uncovered its critical role in pancreatic cancer progression.Abbreviation: ACTB: actin beta; ChIP: chromatin immunoprecipitation; EGF: epidermal growth factor; EIF4EBP1: eukaryotic translation initiation factor 4E binding protein 1; FLCN: folliculin; FNIP1: folliculin interacting protein 1; FNIP2: folliculin interacting protein 2; GAP: GTPase activator protein; GEF: guanine nucleotide exchange factors; GTPase: guanosine triphosphatase; LAMP2: lysosomal associated membrane protein 2; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MEF2: myocyte enhancer factor 2; MEF2A: myocyte enhancer factor 2A; MEF2D: myocyte enhancer factor 2D; MEF2D-3YF: Y131F, Y333F, Y337F mutant; MTOR: mechanistic target of rapamycin kinase; MTORC1: MTOR complex 1; NR4A1: nuclear receptor subfamily 4 group A member 1; RPTOR: regulatory associated protein of MTOR complex 1; RHEB: Ras homolog, mTORC1 binding; RPS6KB1: ribosomal protein S6 kinase B1; RRAG: Ras related GTP binding; RT-qPCR: real time-quantitative PCR; SRC: SRC proto-oncogene, non-receptor tyrosine kinase; TMEM192: transmembrane protein 192; WT: wild-type.

NRF-1 Directly Regulates TFE3 and Promotes the Proliferation of Renal Cancer Cells.

TFE3 Regulates Renal Adenocarcinoma Cell Proliferation Via Activation of the Mtor Pathway.

TFE3 Fusions Escape from Controlling of Mtor Signaling Pathway and Accumulate in the Nucleus Promoting Genes Expression in Xp11.2 Translocation Renal Cell Carcinomas.

The Positive Regulation Loop Between NRF1 and NONO-TFE3 Fusion Promotes Phase Separation and Aggregation of NONO-TFE3 in NONO-TFE3 Trcc.

Inactivation of the FLCN Tumor Suppressor Gene Induces TFE3 Transcriptional Activity by Increasing Its Nuclear Localization

TFE3 fusion proteins drive oxidative metabolism, ferroptosis resistance and general RNA synthesis in translocation renal cell carcinoma

Genome-wide Global Identification of NRF2 Binding Sites in A549 Non-Small Cell Lung Cancer Cells by ChIP-Seq Reveals NRF2 Regulation of Genes Involved in Focal Adhesion Pathways

RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2.

PRCC-TFE3 Fusion-Mediated PRKN/parkin-dependent Mitophagy Promotes Cell Survival and Proliferation in PRCC-TFE3 Translocation Renal Cell Carcinoma

PRCC‐TFE3 Regulates Migration and Invasion of Translocation Renal Cell Carcinomas Via Activation of Drp1‐dependent Mitochondrial Fission

Up-Regulation of NMRK2 Mediated by TFE3 Fusions is the Key for Energy Metabolism Adaption of Xp11.2 Translocation Renal Cell Carcinoma

TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma

NRF3 suppresses breast cancer cell metastasis and cell proliferation and is a favorable predictor of survival in breast cancer.

Hypoxia Induces TFE3 Expression in Head and Neck Squamous Cell Carcinoma.

Nuclear Localization of TEF3-1 Promotes Cell Cycle Progression and Angiogenesis in Cancer

Clinicopathological Features and Prognosis of TFE3-positive Renal Cell Carcinoma

Direct Regulation of FNIP1 and FNIP2 by MEF2 Sustains MTORC1 Activation and Tumor Progression in Pancreatic Cancer.

Nrf1 is Endowed with a Dominant Tumor-Repressing Effect Onto the Wnt/β-Catenin-Dependent and Wnt/β-Catenin-Independent Signaling Networks in the Human Liver Cancer

Nuclear Factor Of Activated T3 Is A Negative Regulator Of Ras-Jnk1/2-Ap-1 - Induced Cell Transformation

Ret finger protein-like 3 promotes tumor cell growth by activating telomerase reverse transcriptase expression in human lung cancer cells.

NRF2 regulates EGF stability through OTUD4 in lung adenocarcinoma